Article
PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer.
Cell death & disease - 3 Jul 2018
Wang Qiang, Shi Yan-Long, Zhou Kai, Wang Li-Li, Yan Ze-Xuan, Liu Yu-Lin, Xu Li-Li, Zhao Shi-Wei, Chu Hui-Li, Shi Ting-Ting, Ma Qing-Hua, Bi Jingwang
Abstract excerpt
Chemotherapy represents an important treatment option for colorectal cancer (CRC), but only half of the patients benefit from these regimens. We explored the potential predicting value and mechanism of PIK3CA mutation in CRC chemotherapy. CRC specimens from 440 patients were retrospectively collected and examined with a fluorescence PCR-based method. The correlation of first-line chemotherapy response and PIK3CA...
Topics
Join the communities discussing this publication.